CureVac Shareholders Face Critical Deadline in BioNTech Takeover
Published on 11/28/2025 at 11:44 | Redaktion boerse-global.de
The independent existence of CureVac as a publicly traded company is drawing to a close. Following decisive shareholder approval, the acquisition by its Mainz-based competitor BioNTech is proceeding, placing investors at a pivotal crossroads. With key deadlines approaching within days, shareholders who delay action risk being caught in the complex mechanics of the takeover process.
During an extraordinary general meeting held this past Tuesday, shareholders expressed near-unanimous support for the transaction. An impressive 99.16% of votes cast were in favor of BioNTech’s public share exchange offer. This resounding endorsement signals that investors see limited prospects for the Tübingen-based company operating independently and prefer its future secured under the larger partner’s Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
